贝伐珠单抗胸腔灌注联合用药治疗恶性胸腔积液的研究进展  

The Research Progress of Bevacizumab in the Treatment of Malignant Pleural Effusion

作　　者：宋长山[1] 杨雨欣 刘格格 叶星宏 张关英 胡炜煜 沈柏儒 SONG Changshan;YANG Yuxin;LIU Gege;YE Xinghong;ZHANG Guanying;HU Weiyu;SHEN Bairu(Chancheng District Central Hospital of Foshan City(Foshan Clinical Medical College of Guangzhou University of Traditional Chinese Medicine),Foshan 528000,China)

机构地区：[1]广东省佛山市禅城区中心医院(广州中医药大学附属佛山临床医学院),广东佛山528000

出　　处：《中国医学创新》2020年第16期157-162,共6页Medical Innovation of China

摘　　要：恶性胸腔积液(malignantpleuraleffusion,MPE)由恶性肿瘤胸膜转移或胸膜间皮瘤引起,它的发生严重影响患者生存质量和提示预后不良.目前MPE的主要治疗方法是,在原发肿瘤进行全身治疗的基础上,对胸腔进行局部治疗(腔穿刺术、胸膜固定术、胸腔埋管引流、胸腔内灌注治疗等),其中胸腔内灌注治疗有着较好的疗效和发展空间.血管内皮生长因子(vascularendothelialgrowthfactor,VEGF)及其受体是一组影响血管生成的重要配体和受体,在控制血管生成中起重要作用,与MPE的发生关系密切.贝伐珠单抗是一种重组的人源化VEGF单克隆抗体,可与内源性VEGF竞争性结合VEGF受体,抑制新血管生成以及降低血管通透性,阻碍胸腔积液形成,延缓肿瘤发展进程.本综述讨论贝伐珠单抗胸腔灌注联合治疗肺癌、晚期消化道癌、恶性胸膜间皮瘤介导的恶性胸腔积液的研究进展,探讨贝伐珠单抗胸腔灌注联合用药的疗效、安全性.Malignant pleural effusion(MPE)is caused by pleural metastasis or mesothelioma,which seriously affects the quality of life and suggests poor prognosis.At present,the main treatment method of MPE is to treat the thoracic cavity locally on the basis of systemic treatment of primary tumor(cavity puncture,pleura fixation,thoracic drainage,intrathoracic perfusion,etc.).Intrathoracic perfusion therapy has better curative effect and development space.Vascular endothelial growth factor(VEGF)and its receptor are a group of important ligands and receptors that affect angiogenesis,play an important role in the control of angiogenesis,and are closely related to the occurrence of MPE.Bevacizumab is a recombinant humanized VEGF monoclonal antibody,which can competitively bind to VEGF receptor with endogenous VEGF,inhibit the formation of new blood vessels and reduce the permeability of blood vessels,hinder the formation of pleural effusion,and delay the development of tumor.This review discusses the research progress of bevacizumab in the treatment of lung cancer,advanced gastrointestinal cancer,malignant pleural mesothelioma mediated malignant pleural effusion,and discusses the efficacy and safety of bevacizumab in the treatment of pleural perfusion.

关 键 词：恶性胸腔积液 贝伐珠单抗 研究进展 

分 类 号：R730.5[医药卫生—肿瘤]